Profile data is unavailable for this security.
About the company
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
- Revenue in USD (TTM)41.22bn
- Net income in USD5.77bn
- Incorporated1900
- Employees114.00k
- LocationAbbott Laboratories100 Abbott Park Road, Abbot ParkABBOTT PARK 60064-3500United StatesUSA
- Phone+1 (224) 667-6100
- Websitehttps://www.abbott.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edwards Lifesciences Corp | 5.62bn | 1.43bn | 41.01bn | 19.80k | 29.37 | 4.30 | 26.26 | 7.30 | 2.37 | 6.93 | 9.32 | 16.18 | 0.5032 | 1.12 | 7.72 | 283,904.00 | 12.76 | 16.63 | 14.98 | 19.12 | 78.63 | 76.71 | 25.35 | 24.84 | 2.89 | -- | 0.0585 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Cencora Inc | 293.96bn | 1.51bn | 47.92bn | 42.00k | 32.40 | 60.91 | 18.18 | 0.163 | 7.51 | 7.51 | 1,467.70 | 3.99 | 4.53 | 15.59 | 12.44 | -- | 2.34 | 1.12 | 11.51 | 4.83 | 3.35 | 3.25 | 0.5168 | 0.2556 | 0.5291 | 19.37 | 0.848 | 65.38 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
| Becton Dickinson and Co | 20.18bn | 1.73bn | 64.28bn | 73.00k | 37.44 | 2.48 | 16.02 | 3.19 | 5.94 | 5.94 | 69.42 | 89.64 | 0.3667 | 3.10 | 7.25 | -- | 3.14 | 2.55 | 3.66 | 2.93 | 45.36 | 45.29 | 8.56 | 7.31 | 0.7405 | 9.56 | 0.437 | 76.96 | 4.16 | 3.14 | 17.41 | 10.83 | -5.40 | 4.29 |
| Medtronic PLC | 33.00bn | 4.29bn | 107.87bn | 95.00k | 25.66 | 2.22 | 15.50 | 3.27 | 3.28 | 3.28 | 25.19 | 37.81 | 0.3664 | 2.03 | 5.41 | 347,326.30 | 4.80 | 4.57 | 5.47 | 5.14 | 65.46 | 66.75 | 13.10 | 13.49 | 1.39 | 9.82 | 0.3677 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
| Boston Scientific Corporation | 15.91bn | 1.79bn | 132.90bn | 48.00k | 74.54 | 6.42 | 43.96 | 8.35 | 1.21 | 1.21 | 10.73 | 14.05 | 0.4412 | 1.91 | 6.91 | 331,458.30 | 4.96 | 2.50 | 5.85 | 2.91 | 69.09 | 68.84 | 11.24 | 6.47 | 1.02 | 6.02 | 0.3419 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Stryker Corp | 21.97bn | 3.59bn | 147.03bn | 52.00k | 41.34 | 7.30 | 31.78 | 6.69 | 9.33 | 9.33 | 57.08 | 52.86 | 0.5368 | 1.56 | 6.27 | 422,576.90 | 8.77 | 6.60 | 10.76 | 7.84 | 63.88 | 63.99 | 16.34 | 13.13 | 1.22 | -- | 0.4345 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Danaher Corp | 23.74bn | 3.93bn | 168.36bn | 61.00k | 43.99 | 3.28 | 27.23 | 7.09 | 5.30 | 5.24 | 32.05 | 71.03 | 0.2821 | 3.39 | 6.11 | 389,213.10 | 4.67 | 5.93 | 5.19 | 6.56 | 59.26 | 58.79 | 16.57 | 19.11 | 1.01 | 21.31 | 0.2546 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
| Intuitive Surgical, Inc. | 7.87bn | 2.24bn | 192.99bn | 13.68k | 87.10 | 12.38 | 69.97 | 24.53 | 6.22 | 6.22 | 21.81 | 43.75 | 0.4848 | 1.98 | 7.44 | 575,234.00 | 13.93 | 12.42 | 15.63 | 13.83 | 66.98 | 67.60 | 28.73 | 26.31 | 3.42 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Thermo Fisher Scientific Inc | 42.37bn | 6.14bn | 196.16bn | 122.00k | 32.16 | 4.00 | 20.87 | 4.63 | 15.95 | 15.95 | 110.12 | 128.08 | 0.4292 | 4.63 | 4.32 | 347,295.10 | 6.28 | 7.79 | 7.36 | 9.11 | 40.77 | 44.94 | 14.62 | 16.76 | 1.26 | 24.08 | 0.4183 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
| Abbott Laboratories | 41.22bn | 5.77bn | 201.08bn | 114.00k | 35.15 | 5.05 | 22.36 | 4.88 | 3.30 | 3.30 | 23.57 | 22.94 | 0.5629 | 2.71 | 6.08 | 361,552.60 | 7.88 | 7.72 | 9.77 | 9.39 | 55.81 | 56.73 | 13.99 | 14.39 | 1.14 | 28.44 | 0.2723 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 160.22m | 9.21% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 86.26m | 4.96% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 76.72m | 4.41% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 65.74m | 3.78% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 53.30m | 3.06% |
| Geode Capital Management LLCas of 30 Sep 2024 | 34.90m | 2.01% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 25.16m | 1.45% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 20.36m | 1.17% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 19.93m | 1.15% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 19.29m | 1.11% |
